Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease characterized by joint involvement, extra-articular manifestations, comorbidities, and increased mortality. In the last few decades, the management of RA has been dramatically improved by the introduction of a treat-to-target app...
Main Authors: | Martina Biggioggero, Andrea Becciolini, Chiara Crotti, Elena Agape, Ennio Giulio Favalli |
---|---|
Format: | Article |
Language: | English |
Published: |
BioExcel Publishing Ltd
2019-10-01
|
Series: | Drugs in Context |
Subjects: | |
Online Access: | https://www.drugsincontext.com/upadacitinib-and-filgotinib:-the-role-of-jak1-selective-inhibition-in-the-treatment-of-rheumatoid-arthritis/ |
Similar Items
-
Different Biomarkers of Response to Treatment with Selective Jak-1 Inhibitors in Rheumatoid Arthritis
by: Maurizio Benucci, et al.
Published: (2023-08-01) -
Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)
by: Hideto Kameda, et al.
Published: (2021-01-01) -
Upadacitinib for Patients with Rheumatoid Arthritis: A Comprehensive Review
by: Raimon Sanmartí, et al.
Published: (2023-02-01) -
Molecular Modeling Insights into Upadacitinib Selectivity upon Binding to JAK Protein Family
by: Amir Taldaev, et al.
Published: (2021-12-01) -
Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials
by: Yoshiya Tanaka, et al.
Published: (2022-11-01)